These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 26395151)
1. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Zou L; Liu M; Wang Y; Lu J; Pang Y Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151 [TBL] [Abstract][Full Text] [Related]
2. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Zhang Z; Li T; Qu G; Pang Y; Zhao Y Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737 [TBL] [Abstract][Full Text] [Related]
3. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo. Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365 [TBL] [Abstract][Full Text] [Related]
4. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Zhang Z; Lu J; Song Y; Pang Y Diagn Microbiol Infect Dis; 2018 Jan; 90(1):31-34. PubMed ID: 29089153 [TBL] [Abstract][Full Text] [Related]
6. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646 [TBL] [Abstract][Full Text] [Related]
7. In Vitro Evaluation of Linezolid and Meropenem Against Clinical Isolates of Multi Drug Resistant Tuberculosis By Mycobacterial Growth Indicator Tube (MGIT) 960. Mirza IA; Satti L; Khan FA; Khan KA J Coll Physicians Surg Pak; 2015 Jun; 25(6):427-30. PubMed ID: 26100995 [TBL] [Abstract][Full Text] [Related]
8. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates]. Coban AY; Bilgin K; Uzun M; Durupinar B Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043 [TBL] [Abstract][Full Text] [Related]
10. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684 [TBL] [Abstract][Full Text] [Related]
11. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data. Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. Zhang Z; Lu J; Liu M; Wang Y; Zhao Y; Pang Y Int J Antimicrob Agents; 2017 Mar; 49(3):383-386. PubMed ID: 28188830 [TBL] [Abstract][Full Text] [Related]
14. Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779 [TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid. Zhang S; Chen J; Cui P; Shi W; Shi X; Niu H; Chan D; Yew WW; Zhang W; Zhang Y Antimicrob Agents Chemother; 2016 Apr; 60(4):2542-4. PubMed ID: 26810645 [TBL] [Abstract][Full Text] [Related]
16. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice. Zhao W; Guo Z; Zheng M; Zhang J; Wang B; Li P; Fu L; Liu S Int J Antimicrob Agents; 2014 Feb; 43(2):148-53. PubMed ID: 24290060 [TBL] [Abstract][Full Text] [Related]
17. [Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB]. Zhang LL; Yang H; Xiao HP; Lu JM; Sha W; Zhang Q Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jun; 39(6):464-8. PubMed ID: 27289577 [TBL] [Abstract][Full Text] [Related]
18. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Zhang Z; Pang Y; Wang Y; Liu C; Zhao Y Int J Antimicrob Agents; 2014 Mar; 43(3):231-5. PubMed ID: 24439458 [TBL] [Abstract][Full Text] [Related]